Space Pharmacology: Variable Gravity as a Perturbation Axis for Cross-Species Drug Translation

A White Paper

Keda Che

Astrava Biosciences

Correspondence: info@astrava.bio · https://astrava.bio

Abstract. Roughly nine in ten drug candidates that enter clinical testing fail, and a dominant share of those failures trace not to the absence of a target but to *translational uncertainty*: efficacy, exposure, or safety that holds in an animal model but does not transfer to humans. We argue that the prevailing toolkit for de-risking translation is constrained by a hidden limitation—ground-based models are *correlated* perturbations of the same biological system, all conducted at terrestrial gravity and along overlapping physiological axes. We define *Space Pharmacology* as the systematic study and exploitation of gravity as a controllable variable across the full pharmaceutical value chain, spanning the drug substance (crystallization, polymorphism, particle-size distribution and hence dissolution and oral bioavailability) and the biological system (cytoskeletal, proteostatic, immune, and DNA-damage responses relevant to disease and drug action). We then propose a unifying construct, *translational invariance*: a mechanism, target, or molecule whose direction and magnitude of effect are conserved across two orthogonal perturbation axes—*species* (mouse, dog, non-human primate, human) and *environment* (terrestrial gravity, simulated microgravity, orbital microgravity and radiation)—is, on this view, materially more likely to transfer to humans. Microgravity is the most orthogonal, least falsifiable-by-ground-replication perturbation presently available. We outline an experimental-design and standardization framework—a ground→simulated-μg→orbital screening funnel, a ground-to-orbit calibration model, and a candidate Perturbation-Invariance / Space-Readiness scoring scheme—and argue that, as commercial launch and recoverable-payload access commoditize, defensible value migrates from *access to space* to the *design of the experiment and the ownership of the standard*.

Keywords: space pharmacology; microgravity; hypergravity; crystallization; polymorphism; cross-species translation; translational invariance; small-molecule drug development.

1. Introduction

Drug development remains an exercise in attrition. Across modalities, the probability that a candidate entering first-in-human studies reaches approval sits near ten percent, and a disproportionate fraction of late, expensive failures reflect a single underlying problem: a result that was true in a preclinical system was not true—or not true in the same way—in people. The field describes this as the "valley of death," but the more precise framing is that preclinical models are *proxies*, and we rarely measure how robust a given signal is to the substitution of one proxy for another.

The standard response has been to add proxies—more cell systems, more species, organoids, organ-on-chip platforms, and increasingly sophisticated *in silico* models. Each addition helps, but all share a structural feature that bounds their discriminative power: they are *correlated* perturbations. A mouse and a dog differ genetically and physiologically, yet both are studied at $1\,g$, in overlapping temperature and pressure regimes, along physiological axes that covary. Two correlated probes of the same system cannot, by construction, reveal a failure mode to which both are blind.

This white paper makes three claims. First, that **gravity is a controllable pharmaceutical variable**, with reproducible, mechanistically distinct effects on both the drug substance and the biological system. Second, that gravity supplies a perturbation axis that is *orthogonal* to the species axis, and that the conjunction of the two—which we call the *species* $\times$ *environment* lattice—measures something neither axis measures alone: *translational invariance*. Third, that the resulting discipline, *Space Pharmacology*, is at an inflection point because the historic bottleneck (access to orbit) is commoditizing, shifting the locus of defensible value to experimental design and standardization.

We are deliberate about scope. Space Pharmacology in our usage is *not* synonymous with "manufacturing drugs in orbit." Orbital manufacturing is one possible downstream application; the discipline is the broader science of how gravity, as a variable, informs and de-risks terrestrial and extraterrestrial drug development alike.

2. Gravity as a Pharmaceutical Variable

2.1 Thermodynamics versus kinetics and transport

Gravity does not alter the thermodynamic equilibria of a chemical system: a solubility curve, a binding constant, or a free-energy landscape is, to first order, gravity-independent. What gravity governs are the *kinetic and hydrodynamic* processes that determine how a system approaches equilibrium. Buoyancy-driven convection and sedimentation are gravity-dependent; suppressing them (in microgravity) shifts mass transport toward a diffusion-limited regime, while amplifying them (in hypergravity) steepens concentration gradients. Because nucleation, crystal growth, dissolution, and—in living systems—the mechanics of cells and fluids are all kinetically and hydrodynamically controlled, gravity acts as a tuning parameter on outcomes even when it leaves the underlying thermodynamics untouched [7, 8].

2.2 Two regimes, two toolsets

Two experimentally accessible regimes flank terrestrial gravity. *Microgravity* (orbital free-fall, or its ground analogs—clinostats, random-positioning machines, rotating-wall vessels) suppresses convection and sedimentation. *Hypergravity* (large-diameter centrifuges) does the opposite, and is fully ground-executable. The historic literature emphasized protein crystallization in microgravity at the high cost of spaceflight; a complementary and far cheaper body of work uses ground-based hypergravity as a rapid screen for the same gravity-sensitivity [3, 4, 1]. A mature Space Pharmacology program treats these as a single continuum of gravity settings, not as separate fields.

3. The Drug Substance under Variable Gravity

For small molecules, crystallization is among the most consequential unit operations: the solid form a molecule adopts sets its dissolution rate and, for poorly soluble compounds, its oral bioavailability and dose—and the relationship between particle size and absorption is well documented [10, 1].

3.1 Nucleation, growth, and particle-size distribution

Reduced gravity suppresses the convective and sedimentary transport that ordinarily feeds growing crystals, yielding a diffusion-limited regime associated with more uniform, lower-defect crystals; this is the basis for decades of microgravity protein-crystallography [6, 5, 7]. The picture for therapeutic macromolecules is concrete: microgravity crystallization of a monoclonal antibody produced a narrow, monomodal particle-size distribution with formulation advantages relevant to subcutaneous delivery [2]. Hypergravity, conversely, steepens local supersaturation gradients and can accelerate nucleation and growth; recent work demonstrates that even within the modest 1–5 g range, the apparent gravity level shifts the particle-size distribution of a small molecule non-monotonically, with the effect surviving vigorous stirring at the millilitre scale [1]. The latter result is important precisely because it shows that gravity-driven supersaturation gradients are not confined to exotic orbital conditions; they perturb routine bench-scale screening platforms.

3.2 Polymorphism, exposure, and intellectual property

Because gravity reshapes nucleation and growth kinetics, it can bias which *polymorph* or which particle-size mode is obtained. Polymorphism is not an academic concern: a metastable form that converts unexpectedly can disable a marketed product, and conversely a deliberately accessed new solid form can improve exposure and constitute fresh composition-of-matter intellectual property. Variable-gravity crystallization therefore connects directly to two levers that decide programs: *in vivo* exposure and patent lifecycle. Commercial recoverable-capsule programs have already crystallized small-molecule active ingredients in orbit and returned them intact, establishing the physical feasibility of orbital solid-form work [1]. For the present argument, the operative point is that the same lever is largely accessible on the ground via hypergravity, making solid-form tuning a cost-disciplined component of a Space Pharmacology program rather than a launch-gated one.

4. The Biological System under Variable Gravity

Gravity perturbs not only how a drug crystallizes but how the biology it acts on behaves. Microgravity is a strong, multi-axis stressor: it removes the mechanical load that cells and tissues are adapted to, alters fluid distribution, and co-occurs in orbit with elevated ionizing radiation. The biological pathways most affected overlap, strikingly, with several high-value drug targets.

- **Cytoskeleton and proteostasis.** Microgravity remodels microtubule and actin networks and perturbs autophagy and aggresome handling—the very machinery whose acetylation status is governed by, for example, HDAC6. A target read out through cytoskeletal and proteostatic biology is therefore probed by the microgravity axis in a mechanistically native way.
- **Innate immunity and sterile inflammation.** Mechanical unloading and mitochondrial stress modulate cytosolic nucleic-acid sensing (cGAS–STING) and inflammasome activity (NLRP3), pathways central to autoimmune, immuno-metabolic, and "inflammaging" indications.
- **DNA damage and the radiation co-stressor.** The orbital environment couples reduced gravity with elevated radiation, directly engaging DNA-damage sensing—again, the substrate of cGAS biology—in a manner ground models cannot reproduce.
- **Musculoskeletal degeneration.** Bone and muscle loss under unloading make microgravity an unusually direct model of sarcopenia and osteoporosis.

The implication is not that microgravity "proves" a mechanism. It is that microgravity applies a perturbation orthogonal to anything a ground model can apply, and a target whose biology remains coherent under that perturbation has passed a test that correlated ground probes could not administer.

5. A Unifying Framework: Translational Invariance

We now state the central construct. Consider the disease–drug system as an object to which we may apply perturbations along two orthogonal axes (Fig. 1). The *species* axis (mouse $\rightarrow$ dog $\rightarrow$ non-human primate $\rightarrow$ human) varies genetic and physiological context. The *environment* axis (1 g $\rightarrow$ simulated μg $\rightarrow$ orbital μg with radiation) varies physical and physiological stress. Each cell of the resulting lattice is a distinct probe.

Definition. A mechanism, target, or molecule exhibits *translational invariance* when the *direction* and—ideally—the *magnitude* of its effect are conserved across the lattice. The thesis of this paper is that invariance is a *transferability criterion*: a candidate that is invariant across species and environment is materially more likely to be valid in humans, while a candidate that collapses under a given perturbation has been falsified along an informative dimension, with the breaking perturbation localizing the liability.



Figure 1. The species × environment perturbation lattice. A candidate whose effect is conserved across both axes (solid path) is more likely to transfer to humans; a candidate that collapses under an orthogonal perturbation (dashed path) is flagged early.

Why the environment axis is not optional. The discriminative power of any such scheme scales with the *orthogonality* of the available perturbations. Ground species models are correlated; microgravity and radiation are, at present, the only perturbations orthogonal enough to expose an entire class of context-dependent non-robustness. Removing the environment axis does not merely drop a feature—it collapses the framework back to conventional cross-species comparison and forfeits the one dimension that ground-only competitors cannot replicate.

An operating loop. Invariance is measured, not assumed, through a closed loop (Fig. 2): *design* the minimal set of species × environment perturbations that best discriminate transferable from non-transferable candidates; *perturb* (ground cross-species and simulated μg at high throughput, sparse orbital runs as calibration anchors); *measure* an invariance score; *certify or falsify*, returning a human-transferability estimate and the perturbation that broke it; and *recalibrate*, updating which perturbations are most informative for the next iteration. The product is therefore not a static prediction but a policy for *designing the cheapest experiment that would prove or disprove transferability*.

6. Experimental Design and Standardization

A discipline is defined less by its phenomena than by its standards—the agreed protocols, controls, and metrics that make results comparable across laboratories. Space Pharmacology currently lacks these. We sketch three components.

6.1 A screening funnel, not a shuttle manifest

Orbital capacity, even as it cheapens, will remain the scarcest and most expensive node in the workflow. Candidates must therefore be triaged on the ground and only a handful ever flown: from a target space of order 10^4, computational and cross-species filters reduce to order 10^2 for wet-lab work, simulated-μg screening reduces to order 10^1, and only 1–3 flagship candidates reach an orbital run, which functions as a calibration anchor rather than a screen. The cardinal rule is directional: candidates flow toward orbit, never the reverse.

Table 1. Proposed dimensions of a translational-invariance / space-readiness assessment. The first five are conventional; the last two are the robustness dimensions introduced here.

Dimension	What it captures
Target conservation	cross-species sequence, structure, pathway dependence
Binding & selectivity	pocket fit, off-target risk
ADMET / developability	solubility, metabolic stability, toxicity window
Cross-species PK/PD	exposure and target-engagement transfer
Biomarker response	patient-relevant readouts and stratification
Environmental robustness	stability of effect under simulated/orbital μg and radiation
Perturbation invariance	consistency of direction/magnitude across the full lattice

6.2 A ground-to-orbit calibration model

Because real orbital data are sparse and costly, the bulk of discriminative power must come from a model that maps ground (1 g) and simulated-μg measurements onto predicted orbital behavior, with occasional true orbital runs serving as ground-truth anchors that recalibrate the mapping. This calibration model—not the launch—is the defensible scientific asset, and it keeps the program cost-disciplined.

6.3 A candidate scoring scheme

We propose extending a conventional translational-readiness assessment with two robustness dimensions (Table 1). The Environmental-Robustness and Perturbation-Invariance scores are intended as community-auditable metrics: versioned, condition-annotated, and reported with uncertainty, so that a "space-ready" or "translation-ready" claim carries a defined, reproducible meaning.

7. Translational and Commercial Implications

Two implications follow for how value is created and captured.

First, **the bottleneck is moving**. Commercial launch and recoverable biological payloads are commoditizing rapidly; reusable vehicles and returnable capsules carrying biological cargo are now operational realities. As access cheapens, the scarce capability is no longer *getting to space* but *knowing which candidate to perturb, how to perturb it, and how to read the result*. The defensible layer is the protocol, the calibration model, and the proprietary data lattice—{species × tissue × disease × gravity × molecule × dose × time}—from which a de facto standard can be built. In short: one need not build rockets to lead this field; one designs the experiments and owns the standard.

Second, **the two faces of the discipline reinforce each other**. The drug-substance face (variable-gravity solid-form engineering) feeds the exposure and intellectual-property levers; the biological face (microgravity perturbation) feeds the target- and mechanism-validation levers. Both attach to the same translational-readiness assessment—the former through the ADMET/exposure dimension, the latter through



Figure 2. The translational-invariance operating loop. Each iteration recalibrates the experimental policy, so the system learns which perturbations most efficiently separate transferable from non-transferable candidates.

the robustness dimensions—so a single program can de-risk both "does the molecule reach its target *in vivo*" and "is the target itself a real, transferable mechanism."

8. A Research Agenda

We highlight open questions whose resolution would mature the field:

- **Fidelity of ground analogs.** How faithfully do clinostats and random-positioning machines reproduce orbital biology for a given pathway, and where does the analogy break?
- **Quantifying invariance.** What is the right statistical formalism for an invariance score that is robust to assay heterogeneity and small orbital sample sizes?
- **Decoupling gravity and radiation.** In orbit the two co-occur; disentangling their contributions is essential for mechanistic interpretation.
- **Solid-form predictability.** Can ground hypergravity reliably predict the polymorph and particle-size landscape accessible in orbit?
- **Standardization governance.** What consortium, reference-protocol, and data-sharing structures are needed for an auditable space-readiness standard?

9. Conclusion

Gravity is a controllable pharmaceutical variable with distinct, reproducible effects on the drug substance and on the biological system. Treated as a perturbation axis orthogonal to species, it enables a measurable construct—*translational invariance*—that functions as a transferability criterion and that ground-only approaches cannot replicate. As launch and recoverable-payload access commoditize, the field's defensible value concentrates in experimental design, the ground-to-orbit calibration model, and an auditable standard. We offer *Space Pharmacology*, and the species $\times$ environment framework, as an organizing program for that work, and as a route to make the perturbation that gravity provides a routine, decision-grade input to drug development rather than a curiosity of spaceflight.

Acknowledgments

The author thanks colleagues at Astrava Biosciences for discussions on cross-species translation and experimental design. This document is a conceptual white paper; it synthesizes published literature and proposes a framework, and does not report new experimental results.

References

[1] Pal, K.; Radocea, A. Gravity as a Knob for Tuning Particle Size Distributions of Small Molecules. *Cryst. Growth Des.* **2024**. doi:10.1021/acs.cgd.3c01274.

[2] Reichert, P.; Prosise, W.; Fischmann, T. O.; *et al.* Pembrolizumab Microgravity Crystallization Experimentation. *npj Microgravity* **2019**, *5*(1), 28.

[3] Lorber, B. Virus and Protein Crystallization under Hypergravity. *Cryst. Growth Des.* **2008**, *8*(8), 2964–2969.

[4] Nanev, C. N.; Dimitrov, I.; Hodjaoglu, F. Hypergravity as a Crystallization Tool. *Ann. N.Y. Acad. Sci.* **2006**, *1077*(1), 172–183.

[5] Vekilov, P. G. Protein Crystal Growth—Microgravity Aspects. *Adv. Space Res.* **1999**, *24*(10), 1231–1240.

[6] McPherson, A.; Greenwood, A.; Day, J. The Effect of Microgravity on Protein Crystal Growth. *Adv. Space Res.* **1991**, *11*(7), 343–356.

[7] Kundrot, C. E.; Judge, R. A.; Pusey, M. L.; Snell, E. H. Microgravity and Macromolecular Crystallography. *Cryst. Growth Des.* **2001**, *1*(1), 87–99.

[8] Snell, E. H.; Helliwell, J. R. Microgravity as an Environment for Macromolecular Crystallization—an Outlook in the Era of Space Stations and Commercial Spaceflight. *Crystallogr. Rev.* **2021**, *27*(1), 3–46.

[9] Yang, H.; Huang, L.; Zhang, F.; *et al.* Gravity on Crystallization of Lysozyme: Slower or Faster? *Cryst. Growth Des.* **2019**, *19*(12), 7402–7410.

[10] Liversidge, G. G.; Cundy, K. C. Particle Size Reduction for Improvement of Oral Bioavailability of Hydrophobic Drugs. *Int. J. Pharm.* **1995**, *125*(1), 91–97.